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1. INTRODUCTION {#jcmm15536-sec-0001}
===============

Renal cell carcinoma is one of the most common malignant tumours of the urogenital system, accounting for about 5% of all new cases of adult males and 3% of new cases of females.[^1^](#jcmm15536-bib-0001){ref-type="ref"} According to statistics in the United States, there are about 73 820 new cases of kidney cancer and 14 770 deaths in 2019.[^2^](#jcmm15536-bib-0002){ref-type="ref"} Clear cell renal cell carcinoma (ccRCC) is the most common and highly malignant pathological type of kidney cancer (accounting for 70%‐85%). About 25%‐30% of ccRCC patients have metastases at first diagnosis, and the 5‐year survival rate of metastatic ccRCC is only 32%. In addition, even ccRCC patients who are initially effective in treatment will have disease progression after a period of time, at which time most patients will lack subsequent effective treatment.

In recent years, new immunotherapy represented by PD‐1/PD‐L1, CTLA4 inhibitors has rapidly emerged in the field of ccRCC treatment and has shown encouraging results for patients with advanced refractory disease.[^3^](#jcmm15536-bib-0003){ref-type="ref"} In 2020, ASCO GU published the 5‐year follow‐up results of the CheckMate 025 study, showing the 5‐year survival rate of monoclonal antibody second‐line treatment is as high as 26%, which demonstrates the advantages of immunotherapy\'s survival benefits and new chapter of treatment strategies for high‐risk ccRCC patients.[^4^](#jcmm15536-bib-0004){ref-type="ref"}, [^5^](#jcmm15536-bib-0005){ref-type="ref"}, [^6^](#jcmm15536-bib-0006){ref-type="ref"} Immune check‐point inhibitors combined with TKI play a variety of roles from the perspective of inducing anti‐tumour immune normalization, inhibiting the development of advanced ccRCC and regulating tumour microenvironment (TME). Its success largely depends on deep understanding of tumour cells and TME interaction.[^7^](#jcmm15536-bib-0007){ref-type="ref"}, [^8^](#jcmm15536-bib-0008){ref-type="ref"} With the deepening of research, more evidence shows that not only the efficacy of immunotherapy depends on the activation of the tumour immune microenvironment, but also the efficacy of traditional treatments such as targeted therapy also depends on the strength of individual anti‐tumour immune response.[^9^](#jcmm15536-bib-0009){ref-type="ref"}, [^10^](#jcmm15536-bib-0010){ref-type="ref"}, [^11^](#jcmm15536-bib-0011){ref-type="ref"} Thus, it is of great significance exploring the underlying mechanism of TME‐driven tumorigenesis and development, improving the efficiency of various existing treatments and discovering novel precise targets for ccRCC therapies.

In TME, tumour cells and immune cells reprogram their metabolic patterns to adapt to the microenvironment of hypoxia, acidity and low nutrition.[^12^](#jcmm15536-bib-0012){ref-type="ref"} For example, tumour cells show enhanced aerobic glycolysis (Warburg effect) but reduce oxidative phosphorylation, which has a great effect on T cell‐mediated anti‐tumour immune response and tumour‐infiltrating myeloid cell activity; macrophages tend to be M2‐type polarization, showing up‐regulated fatty acid synthesis and β‐oxidation.[^13^](#jcmm15536-bib-0013){ref-type="ref"} The activation of tumour cell pro‐cancer signals not only affects its own malignant biological behaviour, but also promotes the development of tumours.[^14^](#jcmm15536-bib-0014){ref-type="ref"} It can also deflect the functional phenotype of tumour‐infiltrating immune cells by changing the metabolic secretion profile and TME of tumour cells and induce the formation of tumour immune escape.[^14^](#jcmm15536-bib-0014){ref-type="ref"}, [^15^](#jcmm15536-bib-0015){ref-type="ref"} Therefore, the metabolic reprogramming of tumour cells and immune cells is crucial for understanding the game process of tumour cells\' evil behaviour, tumour immune response and tumour immune escape and provides new directions for regulating tumour immunity.

The methods of constructing clinical prediction models based on retrospective data help researches realize the prediction of clinical outcomes with several prognostic factors, which is more likely to change our clinical practice and has strong clinical guidance value.[^16^](#jcmm15536-bib-0016){ref-type="ref"} In 2018, RCClnc4 has been demonstrated to have precise prognostic significance in early ccRCC. This study aimed to first establish and validate an effective prognostic metabolic prediction models enrolled large‐scale transcriptome metabolic genes for ccRCC patients. We suggested that the metabolic prediction models (MPMs) classifier could facilitate risk management and treatment strategies for ccRCC patients and identify novel targets in the MPMs co‐network.

2. MATERIALS AND METHODS {#jcmm15536-sec-0002}
========================

2.1. Raw data collection and processing {#jcmm15536-sec-0003}
---------------------------------------

Publicly available mRNA expression and clinical data from ccRCC cohorts were used in this study. Consents and ethical approval of enrolled patients are available in the related original articles where the data sets were published. A total of 718 ccRCC patients from online data sets, including 534 ccRCC and 72 normal samples obtained from The Cancer Genome Atlas (TCGA) database (<https://portal.gdc.cancer.gov/>), 93 ccRCC and 20 normal samples obtained from Clinical Proteomic Tumor Analysis Consortium (CPTAC) and 91 ccRCC samples obtained from RECA‐EU (available in International Cancer Genome Consortium, ICGC), were included in this study.

2.2. Identification of metabolic differentially expressed genes {#jcmm15536-sec-0004}
---------------------------------------------------------------

Forty‐one metabolic pathways were selected according to KEGG pathways atlas. The 911 metabolic genes were utilized for identification of significant metabolic differentially expressed genes (MDEGs) using *Limma* R package (Version 3.6.3) with FDR \< 0.05 and \|logFC\|\>0.5. The intersective metabolic genes between TCGA and CPTAC cohorts were selected for further analyses.

2.3. Development of metabolic prediction models (MPMs) and survival analysis {#jcmm15536-sec-0005}
----------------------------------------------------------------------------

Univariate Cox regression analysis was used to identify prognostic implications of significant MDEGs and presented in forest plot using the *survival* R package. Then, LASSO regression analysis was performed to construct the 20‐mRNA signatures model, metabolic prediction models (MPMs), in ccRCC patients from TCGA and CPTAC cohorts with the *glmnet* and *survival* R package. A risk score of each ccRCC patient was calculated on the basis of MPMs, and ccRCC patients were thus divided into low‐ and high‐risk groups.

For survival analyses, we selected TCGA and CPTAC cohorts with relevant long‐term survival data from patients at the time of surgical resection and pathologically diagnosed as ccRCC. Survival data were of two types: overall survival and progression‐free survival. Log‐rank test in separate curves and Kaplan‐Meier method with 95% confidence intervals (95%CI) were utilized to performing the follow‐up duration analysis. Meanwhile, survival risk assessment of MPMs and hierarchical clustering was shown in patients from TCGA or CPTAC cohort.

2.4. Cox regression analysis and receiver operating characteristic curve construction {#jcmm15536-sec-0006}
-------------------------------------------------------------------------------------

All ccRCC patients from TCGA and CPTAC cohorts with complete transcriptome information and relevant clinical pathologic parameters were included for subsequent analysis. Univariate and multivariable Cox regression analyses were used to evaluate the independent prognostic value of the metabolic clusters using forest plot with the *survival* R package. The receiver operating characteristic curve (ROC) was constructed for traditional clinical pathologic parameter and the risk score of MPMs in both TCGA and CPTAC cohorts using *survival ROC* R package. The area under the curve (AUC) was utilized to assess the predictive value of these prognostic signatures. In addition, Nomogram was developed on the basis of all the independent prognostic factors in TCGA cohort.

2.5. Gene set enrichment analyses {#jcmm15536-sec-0007}
---------------------------------

Gene set enrichment analyses (GSEA) were performed with a permutation test with 1000 times to find the top enriched signal pathways and significantly involved metabolic pathways the Molecular Signatures Database v4.0 (MSigDB) with Adj. *P *\< 0.01 and FDR \< 0.25.

2.6. Tumour microenvironment purity assessment {#jcmm15536-sec-0008}
----------------------------------------------

ESTIMATE algorithm was utilized to evaluate total and immune scores using *estimate* package ([http://r‐forge.rproject.org](http://r-forge.rproject.org); repos = rforge, dependencies = TRUE) in patients from TCGA cohort. Associated between tumour microenvironment (TME) purity and risk score of MPMs or G6PC expression was assessed using Pearson\'s r test.

2.7. Differential G6PC mRNA expression and survival analysis {#jcmm15536-sec-0009}
------------------------------------------------------------

Protein‐protein interaction network of 20 signatures in MPMs was constructed using Search Tool for the Retrieval of Interacting Genes (STRING; [http://string‐db.org](http://string-db.org), version 10.0) online database. Differential expressed *G6PC* level was evaluated between ccRCC and normal samples from TCGA, CPTAC and RECA‐EU cohort using Student\'s t test. Survival analysis of G6PC predicting prognosis ability was performed with GEPIA ([http://gepia.cancer‐pku.cn/detail.php](http://gepia.cancer-pku.cn/detail.php)\#\#\#) in patients from TCGA cohort with cut‐off value set as median. Kaplan‐Meier method with 95% confidence intervals (95% CI) and log‐rank test were used in survival analysis in CPTAC, RECA‐EU and FUSCC. Best cut‐off values were set using X‐tile software. All patients at risk or patients numbers in different risk groups were shown in all survival plots.

2.8. Glucose‐6‐phosphatase (G6Pase) expression in ccRCC and normal samples {#jcmm15536-sec-0010}
--------------------------------------------------------------------------

G6Pase protein expression, coded by G6PC gene, was detected in ccRCC and normal samples from the human protein atlas (<https://www.proteinatlas.org/>) and immunohistochemistry (IHC) data, including staining quantity, intensity, location and patients' data, were available online. Formalin‐fixed, paraffin‐embedded ccRCC tissues and human renal tissues were stained for anti‐G6Pase using ab243319 (Abcam, USA) at 1/3000 dilution in FUSCC cohort and then independently evaluated by two experienced pathologists. The overall IHC score ranging from 0 to 12 was measured based on the multiply of the staining intensity and extent score, as previously described.[^17^](#jcmm15536-bib-0017){ref-type="ref"} Low G6Pase expression group scores from 0 to 2, and high G6Pase group scores from 3 to 12.

2.9. Immune cell infiltrations of G6PC in ccRCC {#jcmm15536-sec-0011}
-----------------------------------------------

TIMER (Tumor IMmune Estimation Resource, <https://cistrome.shinyapps.io/timer/>) is a web server for evaluating systematic various immune cells infiltration and clinical implications. In this study, correlation between infiltration of immune cells and G6PC copy number variation and expression levels were performed.

2.10. Statistical analysis {#jcmm15536-sec-0012}
--------------------------

All analyses were performed in the R (Version 3.6.0) and RStudio (Version 1.2.1335) and GraphPad Prism 7. Unless otherwise stated, results were considered statistically significant when *P*‐value \< 0.05. Two‐sided and *p*‐values less than 0.05 were taken as significant in all tests.

3. RESULTS {#jcmm15536-sec-0013}
==========

3.1. Identification of metabolic differential expressed genes (MDEGs) in both TCGA and CPTAC cohorts {#jcmm15536-sec-0014}
----------------------------------------------------------------------------------------------------

The expression of 911 metabolic genes was collected from 534 ccRCC and 72 normal samples in TCGA cohort. At the same time, 905 of 911 metabolic genes were also found from 56 ccRCC patients and 47 normal people in CPTAC cohort. Then, these 905 metabolic genes were utilized for further analysis. 133 significant MDEGs were identified in 905 metabolic genes and visualized in volcano plot (Figure [1A](#jcmm15536-fig-0001){ref-type="fig"}). Hierarchical partitioning of significant MDEGs was acquired from DNA microarrays based on TCGA cohort (Figure [1B](#jcmm15536-fig-0001){ref-type="fig"}). The mRNA expression of these genes was performed across 534 ccRCC patients and 72 normal people with high in red and low in green. Meanwhile, univariate Cox regression analysis of 58 significant MDEGs (*P *\< 0.05) in TCGA cohort was performed in a forest plot (Figure [1C](#jcmm15536-fig-0001){ref-type="fig"}). Markedly, LASSO regression analysis constructed 20‐mRNA signatures model, metabolic prediction models (MPMs), in ccRCC patients of TCGA or CPTAC cohort. Kaplan‐Meier survival analysis showed significant predictive value of the risk score depending on MPMs in TCGA (Figure [1D](#jcmm15536-fig-0001){ref-type="fig"}) or CPTAC cohort (Figure [1E](#jcmm15536-fig-0001){ref-type="fig"}). High‐risk group was marked in red, and low‐risk group was marked in blue.

![Identification of MDEGs in both TCGA and CPTAC cohorts. A, Identification of significant MDEGs using Limma package in 905 metabolic genes. B, Hierarchical partitioning of significant MDEGs was acquired from DNA microarrays based on TCGA cohort. The mRNA expression of these genes was performed across 534 ccRCC patients and 72 normal people with high in red and low in green. C, Univariate Cox regression analysis of 58 significant MDEGs (*P *\< 0.05) in TCGA cohort was performed in a forest plot. D, The 20‐mRNA signatures model (MPMs) in ccRCC patient was calculated using LASSO regression analysis. Kaplan‐Meier survival analysis showed significant predictive value of the risk score depending on MPMs in TCGA cohort. E, Kaplan‐Meier survival analysis showed significant predictive value of the risk score depending on MPMs in CPTAC cohort. High‐risk group was marked in red, and low‐risk group was marked in blue. MDEGs, metabolic differential expressed genes; MPMs, metabolic prediction models; ccRCC, clear cell renal cell carcinoma; TCGA, the cancer genome atlas; CPTAC, Clinical Proteomic Tumor Analysis Consortium](JCMM-24-9012-g001){#jcmm15536-fig-0001}

3.2. Survival risk assessment of MPMs in TCGA or CPTAC cohort {#jcmm15536-sec-0015}
-------------------------------------------------------------

Survival risk assessment of MPMs consisting of metabolic 20‐mRNA signatures was performed in TCGA or CPTAC cohort. The distribution of survival time, status (Figure [2A](#jcmm15536-fig-0002){ref-type="fig"}), risk score (Figure [2B](#jcmm15536-fig-0002){ref-type="fig"}) and hierarchical partitioning (Figure [2C](#jcmm15536-fig-0002){ref-type="fig"}) of MPMs in tumour and normal samples was shown in TCGA cohort. Meanwhile, the distribution of survival time, status (Figure [2D](#jcmm15536-fig-0002){ref-type="fig"}), risk score (Figure [2E](#jcmm15536-fig-0002){ref-type="fig"}) and hierarchical partitioning (Figure [2F](#jcmm15536-fig-0002){ref-type="fig"}) of MPMs in tumour and normal samples was shown in CPTAC cohort.

![Survival risk assessment of MPMs consists of metabolic 20‐mRNA signatures in TCGA and CPTAC cohorts. A‐C, The distribution of survival time, status, risk score and hierarchical partitioning of 20 signatures in tumour and normal samples was shown in TCGA cohort. D‐F, The distribution of survival time, status, risk score and hierarchical partitioning of 20 signatures in tumour and normal samples was shown in CPTAC cohort. MPMs, metabolic prediction models; TCGA, the cancer genome atlas; CPTAC, Clinical Proteomic Tumor Analysis Consortium](JCMM-24-9012-g002){#jcmm15536-fig-0002}

3.3. Cox regression analysis, ROC analysis and Nomogram of independent prognostic factors and MPMs in ccRCC patients {#jcmm15536-sec-0016}
--------------------------------------------------------------------------------------------------------------------

Univariate and multivariate Cox regression analysis enrolling clinical pathologic parameters and MPMs were illustrated in TCGA and CPTAC cohorts using forest plots (Figure [3A‐D](#jcmm15536-fig-0003){ref-type="fig"}). Risk score of MPMs significantly predicts prognosis for ccRCC patients in TCGA (*P *\< 0.001, HR = 3.131) and CPTAC cohorts (*P *= 0.046, HR = 2.893). In addition, ROC analysis showed robust predictive value of MPMs in TCGA (AUC = 0.768) and CPTAC (AUC = 0.777) cohorts (Figure [3E‐F](#jcmm15536-fig-0003){ref-type="fig"}). A Nomogram was constructed based on 5 independent prognostic factors, including ISUP grade, pathologic M stage, pathologic T stage, AJCC stage and risk score of MPMs, in ccRCC patients (Figure [3G](#jcmm15536-fig-0003){ref-type="fig"}).

![Cox regression analysis, ROC analysis and Nomogram of independent prognostic factors and MPMs in ccRCC patients. A‐D, Univariate and multivariate Cox regression analysis enrolling clinical pathologic parameters and MPMs were illustrated in TCGA and CPTAC cohorts using forest plots. Risk score of MPMs significantly predicts prognosis for ccRCC patients in TCGA (*P *\< 0.001, HR = 3.131) and CPTAC cohorts (*P *= 0.046, HR = 2.893). E‐F, ROC analysis showed robust predictive value of MPMs in TCGA (AUC = 0.768) and CPTAC (AUC = 0.777) cohorts. G, A Nomogram was constructed based on 5 independent prognostic factors, including ISUP grade, pathologic M stage, pathologic T stage, AJCC stage and risk score of MPMs, in ccRCC patients. MPMs, metabolic prediction models; ccRCC, clear cell renal cell carcinoma; TCGA, the cancer genome atlas; CPTAC, Clinical Proteomic Tumor Analysis Consortium](JCMM-24-9012-g003){#jcmm15536-fig-0003}

3.4. KEGG pathways analysis using GSEA {#jcmm15536-sec-0017}
--------------------------------------

GSEA indicated significantly altered KEGG pathways based on differential risk score of MPMs in ccRCC patients with available transcriptomics data from TCGA and CPTAC cohorts. Top 5 significantly altered KEGG pathways in high‐ or low‐risk ccRCC patients were performed in TCGA (Figure [4A](#jcmm15536-fig-0004){ref-type="fig"}) or CPTAC (Figure [4B](#jcmm15536-fig-0004){ref-type="fig"}) cohort. Metabolic significant KEGG pathways in high‐ or low‐risk ccRCC patients were performed in TCGA (Figure S1A) or CPTAC (Figure S1B) cohort. Tumour environment purity was measured using ESTIMATE algorithm, which showed a significant relationship with risk score of MPMs in ccRCC patients from TCGA cohort (*r* ^2^ = 0.2373, *P *\< 0.0001) (Figure [4C](#jcmm15536-fig-0004){ref-type="fig"}). Meanwhile, immune purity in ccRCC environment significantly correlated with risk score of MPMs (*r* ^2^ = 0.3007, *P *\< 0.0001) (Figure [4D](#jcmm15536-fig-0004){ref-type="fig"}).

![GSEA indicated significantly altered KEGG pathways based on differential risk score of MPMs in ccRCC patients with available transcriptomics data from TCGA and CPTAC cohorts. A, Top 5 significantly altered KEGG pathways in high‐ or low‐risk ccRCC patients in TCGA cohort. B, Top 5 significantly altered significant KEGG pathways in high‐ or low‐risk ccRCC patients of CPTAC cohort. C, Tumour environment purity was measured using ESTIMATE algorithm and showed a significant relationship with risk score of MPMs in ccRCC patients from TCGA cohort (*r* ^2^ = 0.2373, *P *\< 0.0001). D, Immune purity in ccRCC environment significantly correlated with risk score of MPMs (*r* ^2^ = 0.3007, *P *\< 0.0001). GSEA, gene set enrichment analysis; KEGG, Kyoto Encyclopedia of Genes and Genomes; MPMs, metabolic prediction models; ccRCC, clear cell renal cell carcinoma; TCGA, the cancer genome atlas; CPTAC, Clinical Proteomic Tumor Analysis Consortium](JCMM-24-9012-g004){#jcmm15536-fig-0004}

3.5. The hub gene in PPI network of MPMs {#jcmm15536-sec-0018}
----------------------------------------

*G6PC*, a hub gene in PPI network of MPMs, shows significant prognostic value in 699 ccRCC patients from TCGA, CPTAC and ICGC cohorts. PPI network was constructed in 20 metabolic mRNA signatures in MPMs (Figure [5A](#jcmm15536-fig-0005){ref-type="fig"}). Interestingly, because of relatively low protein expression in tumour samples, the mRNA and proteome expression levels are in significant linear relationship (Figure S2A, *P *\< 0.001, *r* = 0.371). In transcriptional levels, transcription factor regulation, related LncRNA, targeted miRNA, activation and inhibition of *G6PC* networks were constructed in Figure S2B *G6PC* mRNA expression showed a negatively relationship with tumour environment purity (*r* ^2^ = −0.1012, *P *\< 0.0001) and immune purity (*r* ^2^ = −0.1205, *P *\< 0.0001) in ccRCC (Figure [5B](#jcmm15536-fig-0005){ref-type="fig"} and [C](#jcmm15536-fig-0005){ref-type="fig"}). Differential mRNA expression of *G6PC* in ccRCC and adjacent normal tissues was displayed based on TCGA, CPTAC and RECA‐EU cohorts (Figure [5D‐F](#jcmm15536-fig-0005){ref-type="fig"}). In addition, Kaplan‐Meier survival analysis indicated that low *G6PC* mRNA expression level significantly correlated with poor OS (*P *\< 0.0001, HR = 0.35) and PFS (*P *\< 0.0001, HR = 0.35) in TCGA cohort (Figure [5G](#jcmm15536-fig-0005){ref-type="fig"} and H). Low *G6PC* mRNA expression level was significantly associated with poor prognosis in CPTAC (*P *= 0.0035, HR = 0.218) and RECA‐EU (*P *= 0.0443, HR = 0.446) cohorts (Figure [5I](#jcmm15536-fig-0005){ref-type="fig"} and J).

![*G6PC*, a hub gene in PPI network of MPMs, shows significant prognostic value in 699 ccRCC patients from TCGA, CPTAC and RECA‐EU cohorts. A, PPI network was constructed in 20 metabolic mRNA signatures in MPMs. B and C, *G6PC* mRNA expression showed a negatively relationship with tumour environment purity (*r* ^2^ = −0.1012, *P *\< 0.0001) and immune purity (*r* ^2^ = −0.1205, *P *\< 0.0001) in ccRCC. D‐F, Differential mRNA expression of *G6PC* in ccRCC and adjacent normal tissues was displayed based on TCGA, CPTAC and RECA‐EU (public data at ICGC) cohorts. G‐H, Kaplan‐Meier survival analysis indicated that low *G6PC* mRNA expression level significantly correlated with poor OS (*P *\< 0.0001, HR = 0.35) and PFS (*P *\< 0.0001, HR = 0.35). I, Low *G6PC* mRNA expression level was significantly associated with poor prognosis in CPTAC (*P *= 0.0035, HR = 0.218) and ICGA (*P *= 0.0443, HR = 0.446) cohorts. PPI, protein‐protein interaction; MPMs, metabolic prediction models; ccRCC, clear cell renal cell carcinoma; TCGA, the cancer genome atlas; CPTAC, Clinical Proteomic Tumor Analysis Consortium; ICGC, International Cancer Genome Consortium](JCMM-24-9012-g005){#jcmm15536-fig-0005}

3.6. Differential G6Pase expression predicts outcomes in FUSCC cohort {#jcmm15536-sec-0019}
---------------------------------------------------------------------

A total of 322 ccRCC patients from FUSCC cohort were enrolled. G6Pase was detected high expressed in normal kidney tissues (specifically in tubules cells rather than glomeruli cells), while not detected in ccRCC tissues from the Human Protein atlas (Figure [6A](#jcmm15536-fig-0006){ref-type="fig"}). Meanwhile, significantly elevated G6Pase expression was found in normal tissues compared with ccRCC tissues from FUSCC cohort (Figure [6B](#jcmm15536-fig-0006){ref-type="fig"}). Clinicopathological characteristics in relation to G6Pase expression status were shown in 322 ccRCC patients from FUSCC cohort (Table [S1](#jcmm15536-sup-0004){ref-type="supplementary-material"}). Traditionally clinicopathological factors, such as TNM stage or ISUP grade, were significantly correlated with G6Pase expression level in tumour samples (*P *\< 0.05). In addition, low G6Pase expression was significantly correlated with poor prognosis (*P *\< 0.0001, HR = 0.316) and aggressive progression (*P *\< 0.0001, HR = 0.414) in 322 ccRCC patients from FUSCC cohort (Figure [6C](#jcmm15536-fig-0006){ref-type="fig"} and [D](#jcmm15536-fig-0006){ref-type="fig"}).

![Differential G6Pase expression predicts outcomes in 322 ccRCC patients from FUSCC cohorts. A, G6Pase was detected high expressed in normal kidney tissues (specifically in tubules cells rather than glomeruli cells), while not detected in ccRCC tissues from the Human Protein atlas. B, Significantly elevated G6Pase expression was found in normal tissues compared with ccRCC tissues from FUSCC cohort. C‐D, Low G6Pase expression was significantly correlated with poor prognosis (*P *\< 0.0001, HR = 0.316) and aggressive progression (*P *\< 0.0001, HR = 0.414) in 322 ccRCC patients from FUSCC cohort. ccRCC, clear cell renal cell carcinoma; FUSCC, Fudan University Shanghai Cancer Center](JCMM-24-9012-g006){#jcmm15536-fig-0006}

3.7. Most co‐expressed genes and promoter methylation levels of G6PC in ccRCC {#jcmm15536-sec-0020}
-----------------------------------------------------------------------------

Top 50 co‐expression genes with *G6PC* were extracted and shown in heat map in ccRCC (Figure [7A](#jcmm15536-fig-0007){ref-type="fig"} and [B](#jcmm15536-fig-0007){ref-type="fig"}). Promoter methylation levels of *G6PC* were significantly lower in primary ccRCC samples than normal samples (Figure [7C](#jcmm15536-fig-0007){ref-type="fig"}, *P *\< 0.0001). Promoter methylation levels of *G6PC* significantly climbed with elevated individual cancer stage and were the highest in samples with stage 4 (Figure [7D](#jcmm15536-fig-0007){ref-type="fig"}). Promoter methylation levels of *G6PC* significantly climbed with elevated individual tumour grade and were the highest in samples with grade 4 (Figure [7E](#jcmm15536-fig-0007){ref-type="fig"}). Promoter methylation levels of *G6PC* were significantly higher in ccRCC samples with nodal metastasis compared with pN0 patients (Figure [7F](#jcmm15536-fig-0007){ref-type="fig"}, *P *\< 0.05).

![Most co‐expressed genes and promoter methylation levels of *G6PC* in ccRCC. A and B, Top 50 co‐expression genes with *G6PC* were extracted and shown in heat map in ccRCC. C, Promoter methylation levels of *G6PC* were significantly lower in primary ccRCC samples than normal samples (*P *\< 0.0001). D, Promoter methylation levels of *G6PC* significantly climbed with elevated individual cancer stage and were the highest in samples with stage 4. E, Promoter methylation levels of *G6PC* significantly climbed with elevated individual tumour grade and were the highest in samples with grade 4. F, Promoter methylation levels of *G6PC* were significantly higher in ccRCC samples with nodal metastasis compared with pN0 patients (*P *\< 0.05). ccRCC, clear cell renal cell carcinoma; pN0, pathological negative nodal metastasis status](JCMM-24-9012-g007){#jcmm15536-fig-0007}

3.8. Potential role of G6PC in ccRCC immune microenvironment {#jcmm15536-sec-0021}
------------------------------------------------------------

As the main regulator of glucose production, *G6PC* is highly expressed in liver and kidney tissues. *G6PC* expression is significantly higher in normal tissue compared with renal cell carcinomas, while significantly lower in normal samples compared with hepatocellular carcinoma and cholangiocarcinoma (Figure [8A](#jcmm15536-fig-0008){ref-type="fig"}). At the same time, copy number alteration of *G6PC* significantly correlated with environmental immune cells infiltration level (Figure [8B](#jcmm15536-fig-0008){ref-type="fig"}). Elevated arm‐level deletion of *G6PC* leads to inferior B cell, CD8^+^ cells, CD4^+^ cells, macrophage, neutrophil, dendritic cells infiltration compared with normal samples (*P *\< 0.05). In addition, *G6PC* significantly participates in abnormal immune infiltration of ccRCC cells and microenvironment, showing significantly negative association with check‐point immune signatures, dendritic cells, Th1 cells, MHC class I, cytolytic activity, inflammation promotion, HLA, APC co‐inhibition and co‐stimulation activities (cor.\< −0.7, Figure [8C](#jcmm15536-fig-0008){ref-type="fig"}). Moreover, GSEA indicated that *G6PC* significantly involved in several signal pathways, including bile acid metabolism, fatty acid metabolism, epithelial mesenchymal transition and E2F targets in ccRCC (Figure [8D](#jcmm15536-fig-0008){ref-type="fig"}‐G). A total of 100 up‐ and down‐regulated genes associated with differential *G6PC* expression were then visualized in ccRCC (Figure S3). Spearman\'s correlation and estimated statistical significance between *G6PC* expression and related genes and markers of immune cells were displayed in ccRCC patients using TIMER (**Table ** [**1**](#jcmm15536-tbl-0001){ref-type="table"}).

![Potential role of *G6PC* in pan‐cancers and ccRCC microenvironment. A, As the main regulator of glucose production in the liver, high *G6PC* active expression is found in liver and kidney tissues. *G6PC* expression is significantly higher in normal tissue compared with renal cell carcinoma (KIRC, KIRP, KICH), while significantly lower in normal samples compared with hepatocellular carcinoma and cholangiocarcinoma. B, Copy number alteration of *G6PC* significantly correlated with environmental immune cells infiltration level. Elevated arm‐level deletion of *G6PC* leads to inferior B cell, CD8^+^ cells, CD4^+^ cells, macrophage, neutrophil, dendritic cells infiltration compared with normal samples (*P *\< 0.05). C, *G6PC* significantly participates in abnormal immune infiltration of ccRCC cells and microenvironment, showing significantly negative association with check‐point immune signatures, dendritic cells, Th1 cells, MHC class I, cytolytic activity, inflammation promotion, HLA, APC co‐inhibition and co‐stimulation activities (cor.\<−0.7). D‐G, GSEA indicated that *G6PC* significantly involved in several signal pathways, including bile acid metabolism, fatty acid metabolism, epithelial mesenchymal transition and E2F targets in ccRCC. ccRCC, clear cell renal cell carcinoma; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; KICH, kidney Chromophobe; GSEA, gene set enrichment analysis](JCMM-24-9012-g008){#jcmm15536-fig-0008}

###### 

Immune cells infiltrations in relationship to G6PC expression

  Description           Gene markers      G6PC                             
  --------------------- ----------------- ---------- ---------- ---------- ----------
  CD8 + T cell          CD8A              −0.032     .468       −0.004     .94
  CD8B                  −0.008            .862       0.022      .637       
  T cell (general)      CD3D              −0.081     .061       −0.052     .204
  CD3E                  −0.067            .124       −0.037     .427       
  CD2                   −0.071            .104       −0.042     .369       
  B cell                CD19              −0.18      \*\*\*\*   −0.151     \*\*
  CD79A                 −0.222            \*\*\*\*   −0.209     \*\*\*\*   
  Monocyte              CD86              −0.157     \*\*\*     −0.142     \*\*
  CD115 (CSF1R)         −0.146            \*\*\*     −0.132     \*\*       
  TAM                   CCL2              0.083      .054       0.108      \*
  CD68                  −0.084            .054       −0.126     \*\*       
  IL10                  −0.109            \*         −0.087     .062       
  M1 Macrophage         INOS (NOS2)       0.194      \*\*\*\*   0.216      \*\*\*\*
  IRF5                  −0.089            \*         −0.112     \*         
  COX2 (PTGS2)          −0.252            \*\*\*\*   −0.212     \*\*\*\*   
  M2 Macrophage         CD163             −0.092     \*         −0.095     \*
  VSIG4                 −0.232            \*\*\*\*   −0.234     \*\*\*\*   
  MS4A4A                −0.136            \*\*       −0.12      \*\*       
  Neutrophils           CD66b (CEACAM8)   0.064      .138       0.047      .311
  CD11b (ITGAM)         −0.093            \*         −0.085     .069       
  CCR7                  −0.085            \*         −0.08      .087       
  Natural killer cell   KIR2DL1           0.108      \*         0.089      .055
  KIR2DL3               0.087             \*         0.065      .163       
  KIR2DL4               −0.057            .192       −0.053     .252       
  KIR3DL1               0.163             \*\*\*     0.137      \*\*       
  KIR3DL2               0.094             \*         0.077      .101       
  KIR3DL3               −0.052            .232       −0.051     .276       
  KIR2DS4               0.025             .567       0.02       .67        
  Dendritic cell        HLA‐DPB1          0.025      .572       0.038      .411
  HLA‐DQB1              0.073             .091       0.081      .082       
  HLA‐DRA               0.022             .615       0.028      .553       
  HLA‐DPA1              0.04              .355       0.062      .186       
  BDCA‐1 (CD1C)         0.148             \*\*\*     0.185      \*\*\*\*   
  BDCA‐4 (NRP1)         0.128             \*\*       0.136      \*\*       
  CD11c (ITGAX)         −0.125            \*\*       −0.123     \*\*       
  Th1                   T‐bet (TBX21)     0.076      .079       0.089      .057
  STAT4                 −0.108            \*         −0.108     \*         
  STAT1                 −0.061            .163       −0.048     .304       
  IFN‐γ (IFNG)          −0.089            \*         −0.078     .095       
  TNF‐α (TNF)           0.008             .861       0.023      .623       
  Th2                   GATA3             −0.173     \*\*\*\*   −0.083     .073
  STAT6                 0.08              .066       0.056      .227       
  STAT5A                −0.167            \*\*\*     −0.151     \*\*       
  IL13                  −0.009            .844       −0.027     .565       
  Tfh                   BCL6              −0.198     \*\*\*\*   −0.238     \*\*\*\*
  IL21                  −0.137            \*\*       −0.13      \*\*       
  Th17                  STAT3             −0.091     \*         −0.081     .081
  IL17A                 −0.044            .31        −0.022     .636       
  Treg                  FOXP3             −0.217     \*\*\*\*   −0.212     \*\*\*\*
  CCR8                  −0.111            \*         −0.106     \*         
  STAT5B                0.343             \*\*\*\*   0.325      \*\*\*\*   
  TGFβ (TGFB1)          −0.325            \*\*\*\*   −0.315     \*\*\*\*   
  T cell exhaustion     PD‐1 (PDCD1)      −0.068     .116       −0.051     .273
  CTLA4                 −0.115            \*\*       −0.102     \*         
  LAG3                  −0.115            \*\*       −0.095     \*         
  TIM‐3 (HAVCR2)        0.173             \*\*\*\*   0.157      \*\*\*     
  GZMB                  −0.043            .319       −0.034     .46        

\* *P*\< 0.05; \*\* *P*\< 0.01; \*\*\* *P*\< 0.001; \*\*\*\* *P*\< 0.0001.
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4. DISCUSSION {#jcmm15536-sec-0022}
=============

The control of energy metabolism in human is a complex and cautious process, and metabolic disorders may lead to the occurrence and development of a variety of diseases.[^18^](#jcmm15536-bib-0018){ref-type="ref"} For instance, abnormal lipid metabolism may reduce growth and impair fertility, while disorders in glucose metabolism can lead to diabetes and hypertension.[^19^](#jcmm15536-bib-0019){ref-type="ref"}, [^20^](#jcmm15536-bib-0020){ref-type="ref"} Importantly, the relationship between metabolic reprogramming and tumorigenesis has been paid more and more attention in recent years. Steven L. Gonias et al claimed that activation of lipid metabolism promotes tumour cell survival and tumour progression in pancreatic cancer.[^21^](#jcmm15536-bib-0021){ref-type="ref"} Some studies found that abnormal glucose metabolism plays an key role in tumorigenesis.[^22^](#jcmm15536-bib-0022){ref-type="ref"}, [^23^](#jcmm15536-bib-0023){ref-type="ref"} Metabolic changes promote the proliferation of tumours microenvironment and also help us better understand the alterations of characteristics phenotypes and immune microenvironment of cancers.[^24^](#jcmm15536-bib-0024){ref-type="ref"} For example, the activation of PI3K/AKT/mTOR and other carcinogenic pathways is related to the changes of bioenergy pathways such as glycolysis, fatty acid and glutamine metabolism, which provides a new target for tumour therapy.[^25^](#jcmm15536-bib-0025){ref-type="ref"}, [^26^](#jcmm15536-bib-0026){ref-type="ref"}, [^27^](#jcmm15536-bib-0027){ref-type="ref"}

ccRCC is one of the most common types of renal cell carcinoma in the world, and it is associated with poor prognosis because of its high metastasis and recurrence rate.[^1^](#jcmm15536-bib-0001){ref-type="ref"}, [^28^](#jcmm15536-bib-0028){ref-type="ref"} Metabolic reprogramming in ccRCC is most often associated with mutations in VHL, which occur in about 90% of cases.[^29^](#jcmm15536-bib-0029){ref-type="ref"} In VHL mutant diseases, activation of metabolic pathways mediated by HIF leads to the activation of pathways contrary to the effects of hypoxia in normoxic environments.[^30^](#jcmm15536-bib-0030){ref-type="ref"} Previous studies found that ccRCC produces energy mainly through the accumulation of lactic acid,[^31^](#jcmm15536-bib-0031){ref-type="ref"}, [^32^](#jcmm15536-bib-0032){ref-type="ref"} which is also called Warburg effect or aerobic glycolysis. HIF‐1α, as the obvious driving force behind the Warburg effect in ccRCC, increases the expression of GLUT‐1, thus promoting intracellular glucose uptake.[^33^](#jcmm15536-bib-0033){ref-type="ref"}, [^34^](#jcmm15536-bib-0034){ref-type="ref"} Interestingly, complex components in tumour microenvironment could exhibit metabolic stress on immune cells infiltrations, which can lead to immunosuppressive and tumour immune evasion.[^24^](#jcmm15536-bib-0024){ref-type="ref"} The increased expression of GLUT‐1 in ccRCC is associated with a decrease in the number of infiltrated CD8^+^T cells, suggesting that glucose metabolism may suppress the immune system through another mechanism in renal cell carcinoma.[^35^](#jcmm15536-bib-0035){ref-type="ref"} Normally, elevated glycolysis increases tumours immunity, immune check‐point factors (PD‐L1) expression levels on tumour cells, and thus imposed a favourable immunotherapy response in cancers.[^36^](#jcmm15536-bib-0036){ref-type="ref"} Thus, the relationship between metabolic reprogramming and ccRCC microenvironment was worthy of further exploration.

G6PC (Glucose‐6‐Phosphatase Catalytic Subunit) is a protein coding gene, and it is closely associated with glycogen storage disease[^37^](#jcmm15536-bib-0037){ref-type="ref"} and hypoglycaemia.[^38^](#jcmm15536-bib-0038){ref-type="ref"} Gross, D. N et al claimed that G6PC was related to FoxO1 signalling pathway[^39^](#jcmm15536-bib-0039){ref-type="ref"} and G6PC plays a key role in Hexose transport.[^40^](#jcmm15536-bib-0040){ref-type="ref"} This study found that expression of G6PC in ccRCC is much lower than that of normal tissues in multiple cohorts including TCGA, CPTAC, ICGC and FUSCC cohorts. And survival analyses indicated that expression level of G6PC was positively correlated with patients' outcome, suggesting that G6PC may have tumour suppressive properties in ccRCC. Studies have focused on exploring the biological significance of G6PC. Ting Guo et al [^41^](#jcmm15536-bib-0041){ref-type="ref"} found that G6PC plays a dual role in both glucose metabolism and cell cycle regulation in ovarian cancer, which makes it a promising therapeutic target. Glycogen storage disease type I (GSDI) is a rare hereditary pathology characterized by glucose‐6‐phosphatase (G6Pase) deficiency. Monika Gjorgjieva et al found occurrence of ccRCC in mouse model with a kidney‐specific G6Pase deficiency (K. G6pc‐/‐ mice).[^42^](#jcmm15536-bib-0042){ref-type="ref"} It is not a unique instance, but has its counterpart. Cho Jun‐Ho *et al* [^43^](#jcmm15536-bib-0043){ref-type="ref"} also claimed that G6PC could inhibit the occurrence of hepatic carcinoma, which is compatible with our hypothesis. In view of the possible inhibitory effect on tumour cells of G6PC, it may shed light on the management of ccRCC.

Thus, our research has some limitations. The main thing is the retrospective design of this study. Multicenter prospective studies are needed to verify the conclusions. Also, we did not validate prognostic specificity and sensitivity of MPMs in ccRCC patients from a real‐world cohort; thus, we presented prognostic value of MPMs in CRTAC and validate role of G6PC in \> 1000 ccRCC patients from TCGA, CPTAC, RECA‐EU, HPA and FUSCC (validation cohort in China) cohorts. In addition, there is an urgent need for in vitro and in vivo experiments to explore potential effective functions of G6PC and reveal the underlying mechanisms.

5. CONCLUSION {#jcmm15536-sec-0023}
=============

In conclusion, this study first provided the opportunity to comprehensively elucidate the prognostic MDEGs landscape, established novel prognostic model MPMs using large‐scale ccRCC transcriptome data and identified G6PC as potential prognostic targets in 1040 ccRCC patients from multiply cohorts. These finding could assist in managing risk assessment and shed valuable insights into treatment strategies of ccRCC.
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